Edoxaban vs. Apixaban in AF with CAD: Net Benefit

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4, interventional trial compares two NOACs, edoxaban and apixaban, in patients who have atrial fibrillation plus coronary artery disease. The objective is to determine whether edoxaban offers a non-inferior net adverse clinical events balance compared with apixaban. Participants must be at least 19 years old and require oral anticoagulation for AF, with documented CAD, and must meet specified renal and bleeding criteria. The study will assess thromboembolism, bleeding, and other clinical outcomes to inform anticoagulation choices in this high-risk population. Samsung Medical Center leads the study with no listed collaborators, and the setting is Seoul, Korea.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients must be at least 19 years of age
* Patients with AF requiring oral anticoagulation therapy (CHA2DS2-VaSc 2 or more)
* Documented coronary artery disease, defined as at least one of the following: history of percutaneous coronary intervention (PCI), history of coronary artery bypass grafting (CABG), major epicardial coronary artery stenosis ≥50% on coronary computed tomography angiography (CCTA) or invasive coronary angiography
* Patients who can understand risks, benefits and treatment alternatives and sign informed consent voluntarily.

Exclusion Criteria:

* Known hypersensitivity or contraindications to study medications (apixaban or edoxaban)
* Severe renal impairment (creatinine clearance \<15 mL/min) or dialysis
* Active major bleeding
* Indication requiring alternative anticoagulation (e.g., mechanical valve surgery or moderate / severe mitral stenosis)
* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
* Pregnant or lactating women

Where it's running

• Samsung Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Joo-yong Hahn, MD, PhD — Samsung Medical Center
• Study coordinator: Joo-Yong Hahn, MD, PhD
• Email: Jooyong.hahn@gmail.com
• Phone: 82-2-3410-6653

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated care for older patients with atrial fibrillation

  This study is testing a new team-based care approach for older patients with atrial fibrillation and other health issues to see if it helps them manage their condition better than regular care.

  Recruiting at 50 sites Heart Care Foundation · Haskovo and 49 other locations · NCT06775028

• Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation

  This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.

  Recruiting St. Josefs-Hospital Wiesbaden GmbH · Wiesbaden · NCT07910370

• Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation

  This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.

  Recruiting East Sussex Healthcare NHS Trust · Eastbourne · NCT07900685

• Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF

  This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.

  Recruiting Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07874763

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes

  This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.

  Recruiting at 5 sites Insel Gruppe AG, University Hospital Bern · Zabrze and 4 other locations · NCT07852221

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.